About Abcam plc
As an innovator in reagents and tools, Abcams purpose is to serve life science researchers globally to achieve their mission faster.
Providing the research and clinical communities with tools and scientific support, the Company offers highly validated antibodies, assays, and other research tools to address important targets in critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life sciences, Abcams ambition is to be the most influential company in life
sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health.
Abcams worldwide customer base of approximately 750,000 life science researchers uses Abcams antibodies, reagents,
biomarkers, and assays. By actively listening to and collaborating with these researchers, the Company continuously advances its portfolio to address their needs. A transparent program of customer reviews and datasheets, combined with
industry-leading validation initiatives, gives researchers increased confidence in their results.
Founded in 1998 and headquartered
in Cambridge, UK, the Company has served customers in more than 130 countries. Abcams American Depositary Shares (ADSs) trade on the Nasdaq Global Select Market (Nasdaq: ABCM).
For more information, please visit www.abcam.com or www.abcamplc.com
Forward-Looking Statements
This
announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by the following words: may, might,
will, could, would, should, expect, plan, anticipate, intend, seek, believe, estimate, predict,
potential, continue, contemplate, possible or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. They are not historical
facts, nor are they guarantees of future performance. Any express or implied statements contained in this announcement that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation,
statements regarding Abcams portfolio and ambitions, and our future results of operations and financial position such as our outlook for FY2023 and performance goals for FY2024 are neither promises nor guarantees, but involve known and unknown
risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation: challenges in implementing our strategies for revenue growth in light of competitive challenges; the development
of new products or the enhancement of existing products, and the need to adapt to significant technological changes or respond to the introduction of new products by competitors to remain competitive; our customers discontinuing or spending less on
research, development, production or other scientific endeavors; failing to successfully identify or integrate acquired businesses or assets into our operations or fully recognize the anticipated benefits of businesses or assets that we acquire; the
ongoing COVID 19 pandemic, including variants, continues to affect our business, including impacts on our operations and supply chains; failing to successfully use, access and maintain information systems and implement new systems to handle our
changing needs; cyber security risks and any failure to maintain the confidentiality, integrity and availability of our computer hardware, software and internet applications and related tools and functions; failing to successfully manage our current
and potential future growth; any significant interruptions in our operations; our products failing to satisfy applicable quality criteria, specifications and performance standards; failing to maintain and enhance our brand and reputation; ability to
react to unfavorable geopolitical or economic changes that affect life science funding; failing to deliver on transformational growth projects; our dependence upon management and highly skilled employees and our ability to attract and retain these
highly skilled employees; and as a foreign private issuer, we are exempt from a number of rules under the U.S. securities laws and Nasdaq corporate governance rules and are permitted to file less information with the SEC than U.S. companies, which
may limit the information available to holders of our American Depositary Shares (ADS); and the other important factors discussed under the caption Risk Factors in Abcams Annual Report on Form 20-F for the year ended December 31, 2022 (Annual Report) with the U.S. Securities and Exchange Commission (SEC) on March 20, 2023, which is available on the SEC website at
www.sec.gov, as such factors may be updated from time to time in Abcams subsequent filings with the SEC. Any forward-looking statements contained in this announcement speak only as of the date hereof and accordingly undue reliance
should not be placed on such statements. Abcam disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this announcement, whether as a result of new information, future events or otherwise, other than
to the extent required by applicable law.
Use of Non-IFRS Financial Measures
To supplement our audited financial results prepared in accordance with International Financial Reporting Standards (IFRS) we
present Adjusted Operating Profit, Adjusted Operating Profit Margin, Total Constant Exchange Rate Revenue (CER revenue), which are financial measures not prepared in accordance with IFRS
(non-IFRS financial measures). We believe that the presentation of these non-IFRS financial measures provide useful information about our operating results
and enhances the overall understanding of our past financial performance and future prospects, allowing for greater transparency with respect to key measures used by management in its financial and operational decision making. These non-IFRS financial measures are supplemental in nature as they include and/or exclude certain items not included and/or excluded in the most directly comparable IFRS financial measures and should not be considered
in isolation, or as a substitute for, financial measures prepared in accordance with IFRS. Further, other companies may calculate these non-IFRS financial measures differently than we do, which may limit the
usefulness of those measures for comparative purposes.